Abstract

BackgroundThe pleiotrophic cytokine interleukin (IL)-13 features prominently in allergic and inflammatory diseases. In allergic asthma, IL-13 is well established as an inducer of airway inflammation and tissue remodeling. We demonstrated previously that IL-13 induces release of transforming growth factor-α (TGFα) from human bronchial epithelial cells, with proliferation of these cells mediated by the autocrine/paracrine action of this growth factor. TGFα exists as an integral membrane protein and requires proteolytic processing to its mature form, with a disintegrin and metalloproteinase (ADAM)17 responsible for this processing in a variety of tissues.MethodsIn this study, normal human bronchial epithelial (NHBE) cells grown in air/liquid interface (ALI) culture were used to examine the mechanisms whereby IL-13 induces release of TGFα and cellular proliferation. Inhibitors and antisense RNA were used to examine the role of ADAM17 in these processes, while IL-13-induced changes in the intracellular expression of TGFα and ADAM17 were visualized by confocal microscopy.ResultsIL-13 was found to induce proliferation of NHBE cells, and release of TGFα, in an ADAM17-dependent manner; however, this IL-13-induced proliferation did not appear to result solely from ADAM17 activation. Rather, IL-13 induced a change in the location of TGFα expression from intracellular to apical regions of the NHBE cells. The apical region was also found to be a site of significant ADAM17 expression, even prior to IL-13 stimulation.ConclusionResults from this study indicate that ADAM17 mediates IL-13-induced proliferation and TGFα shedding in NHBE cells. Furthermore, they provide the first example wherein a cytokine (IL-13) induces a change in the intracellular expression pattern of a growth factor, apparently inducing redistribution of intracellular stores of TGFα to the apical region of NHBE cells where expression of ADAM17 is prominent. Thus, IL-13-induced, ADAM17-mediated release of TGFα, and subsequent epithelial cell proliferation, could contribute to the epithelial hypertrophy, as well as other features, associated with airway remodeling in allergic asthma.

Highlights

  • The pleiotrophic cytokine interleukin (IL)-13 features prominently in allergic and inflammatory diseases

  • ADAM17 induced cellular proliferation as did IL-13 and transforming growth factor-α (TGFα) (Fig. 1b). These results indicate that normal human bronchial epithelial (NHBE) cells express TGFα on the extracellular membrane in a form that is amenable to proteolytic cleavage by ADAM17

  • This conclusion is supported by data demonstrating that the proliferation and growth factor shedding are inhibited by antisense oligonucleotides directed against ADAM17, while rhADAM17-induced proliferation of NHBE cells can be blocked with neutralizing anti-TGFα antibodies

Read more

Summary

Introduction

The pleiotrophic cytokine interleukin (IL)-13 features prominently in allergic and inflammatory diseases. Cytokines and growth factors serve to enhance or resolve inflammation-induced changes in biological structures [4,5] Such a coordinated relationship between the cytokine interleukin-13 (IL-13) and the growth factor, transforming growth factor-α (TGFα), was demonstrated previously by our laboratory in normal human bronchial epithelial (NHBE) cells. IL-13 has been shown to play a role in the development of mucous cell hyperplasia [9,10,11], in activating matrix metalloproteinases [12], and in inducing expression of epithelium-derived growth factors (i.e. TGFα [6], TGFβ [13]) and chemokines (i.e. eotaxin [14], MCP-3 [15]) These released factors, in turn, affect neighboring epithelial cells as well as other cell types within the airway walls such as fibroblasts and smooth muscle cells [16]. While it is well documented that epithelial cells, including those of the airways, produce and release growth factors [17], the mechanism, or mechanisms, regulating cytokine-induced release of growth factors has not been fully elucidated

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.